DocGo Inc. (DCGO): Nasdaq/NYSE listing notice — DocGo receives Nasdaq deficiency notice for bid price below $1.00

DocGo Inc.

Nasdaq notified DocGo on Jan 26, 2026 of non-compliance with minimum bid price rule; closing bid below $1.00 from Dec 9, 2025 to Jan 23, 2026.
Company has 180 days, until July 27, 2026, to regain compliance by closing bid >= $1.00 for 10 consecutive business days.
If not compliant by July 27, DocGo may qualify for a second 180-day period if it meets other standards and intends to cure.
DocGo is evaluating options including a potential reverse stock split to regain compliance.
Listing remains fully effective; no immediate delisting action.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

DocGo Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 26, 2026, DocGo Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from December 9, 2025 to January 23, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (the “Minimum Bid Requirement”).

View on SEC.gov

Browse all listing & compliance notices →

DocGo Inc. filing history →

Source: SEC EDGAR

accession 0001822359-26-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.